Program
apixaban
Also written as “Apixaban”, “Apixaban 5 MG” and “Apixaban 5 mg Oral Tablet”.
Its studies are mostly in Venous Thrombosis · Atrial Fibrillation · Thrombosis · Acute Coronary Syndrome · Venous Thromboembolism, led by 7 companies.
Drug pageApixaban: every studyMany companies study it; this page follows only the 37 they lead. All 179 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 260 open or running | phase 4since Jun 6, 2013 | Nov 22, 2004 | none ahead |
| Pfizerits history only | 60 open or running | phase 4since Feb 5, 2014 | Nov 5, 2008 | none ahead |
| Artivionits history only | 10 open or running | phase 3since Oct 9, 2019 | Oct 9, 2019 | none ahead |
| Dexa Medica Groupits history only | 10 open or running | phase 1since Feb 5, 2025 | Feb 5, 2025 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Sep 4, 2023 | Sep 4, 2023 | none ahead |
| Scotmann Pharmaceuticalsits history only | 10 open or running | phase 2since Oct 21, 2021 | Oct 21, 2021 | none ahead |
| TAHO Pharmaceuticalsits history only | 10 open or running | early phase 1since Jul 24, 2023 | Jul 24, 2023 | none ahead |
Also a collaborator on its studies: Link Medical Research AB, Parexel and PT Equilab International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 20 studies since Nov 22, 2004.
- Jan 10, 20143 phase 1 studiesBristol-Myers Squibb · NCT02034591, NCT02034578, NCT02034565
- Feb 5, 2014Phase 4 study in Atrial FibrillationPfizer · NCT02100228 · 1,500 enrolled · United States, Belgium, Canada and more
- Mar 28, 2014Phase 1 study in ThrombosisBristol-Myers Squibb · NCT02101112 · 69 enrolled
- Oct 9, 20142 phase 1 studies in N/A - Healthy SubjectsBristol-Myers Squibb · NCT02262533, NCT02262520
- Jan 21, 2015Phase 3 study in LymphomaBristol-Myers Squibb · NCT02369653 · 512 enrolled · United States, Australia, Belgium and more
- Apr 9, 2015Phase 4 study in Acute Coronary SyndromeBristol-Myers Squibb · NCT02415400 · 4,614 enrolled · United States, Argentina, Australia and more
- May 26, 2015Phase 4 study in Venous ThromboembolismBristol-Myers Squibb · NCT02464969 · 229 enrolled · United States, Australia, Austria and more
- Sep 19, 2016Phase 1 study in Venous ThromboembolismBristol-Myers Squibb · NCT02912234 · 20 enrolled · United States
- Nov 18, 2016Phase 2 study in ThrombosisBristol-Myers Squibb · NCT02981472 · 192 enrolled · United States, Argentina, Australia and more
- Oct 9, 2019Artivion’s first study: phase 3 study in Aortic Valve DiseaseNew to ArtivionArtivion · NCT04142658 · 863 enrolled · United States
- Oct 21, 2021Scotmann Pharmaceuticals’ first study: phase 2 study in COVID-19New to Scotmann PharmaceuticalsScotmann Pharmaceuticals · NCT05088928 · 40 enrolled · Pakistan
- Jul 24, 2023TAHO Pharmaceuticals’ first study: early phase 1 study in FastingNew to TAHO PharmaceuticalsTAHO Pharmaceuticals · NCT05995119 · 12 enrolled · United States
- Sep 4, 2023Humanis Saglık Anonim Sirketi’s first study: phase 1 study in Antithrombic DrugNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT06043297 · 30 enrolled · India
- Feb 5, 2025Dexa Medica Group’s first study: phase 1 study in HealthNew to Dexa Medica GroupDexa Medica Group · NCT06817811 · 24 enrolled · Indonesia
TargetBeta
“Coagulation factor X inhibitor”ChEMBL 37, by rule
Other programs on F10
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rivaroxabanrule | Bayer | phase 4 | 77 |
| emicizumabrule | Hoffmann-La Roche | phase 4 | 13 |
| Factor Xrule | kedrion-s-p-a | phase 3 | 1 |
Studies
All 37 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06817811Health · Indonesia | 1 | Completed | Dexa Medica Group | Apr 24, 2021 | 24 |
| NCT06043297Antithrombic Drug · India | 1 | Completed | Humanis Saglık Anonim Sirketi | Mar 6, 2023 | 30 |
| NCT05995119Fasting · United States | Early 1 | Completed | TAHO Pharmaceuticals | Dec 28, 2022 | 12 |
| NCT05088928COVID-19 · Pakistan | 2 | UNKNOWN | Scotmann Pharmaceuticals | May 30, 2022 | 40 |
| NCT04142658Aortic Valve Disease · United States | 3 | Terminated | Artivion | Dec 12, 2022 | 863 |
| NCT02981472Thrombosis · United States, Argentina, Australia and more | 2 | Completed | Bristol-Myers Squibb | Oct 18, 2021 | 192 |
| NCT02912234Venous Thromboembolism · United States | 1 | Completed | Bristol-Myers Squibb | Oct 2016 | 20 |
| NCT02464969Venous Thromboembolism · United States, Australia, Austria and more | 4 | Completed | Bristol-Myers Squibb | Apr 30, 2024 | 229 |
| NCT02415400Acute Coronary Syndrome · United States, Argentina, Australia and more | 4 | Completed | Bristol-Myers Squibb | Nov 10, 2018 | 4,614 |
| NCT02369653Lymphoma · United States, Australia, Belgium and more | 3 | Completed | Bristol-Myers Squibb | Jul 7, 2021 | 512 |
| NCT02262533N/A - Healthy Subjects · United States | 1 | Completed | Bristol-Myers Squibb | Jun 2007 | 15 |
| NCT02262520N/A - Healthy Subjects | 1 | Completed | Bristol-Myers Squibb | Mar 2006 | 24 |
| NCT02101112Thrombosis | 1 | Completed | Bristol-Myers Squibb | May 2014 | 69 |
| NCT02100228Atrial Fibrillation · United States, Belgium, Canada and more | 4 | Completed | Pfizer | Feb 8, 2017 | 1,500 |
| NCT02034591Healthy Subjects · United States | 1 | Completed | Bristol-Myers Squibb | Nov 2011 | 37 |
| NCT02034578Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Aug 2011 | 75 |
| NCT02034565Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Mar 2010 | 48 |
| NCT01884350Non-valvular Atrial Fibrillation · Belgium, France, Germany and more | 4 | Completed | Bristol-Myers Squibb | Jan 20, 2016 | 1,217 |
| NCT01884337Anticoagulation · India | 4 | Completed | Bristol-Myers Squibb | Jun 4, 2018 | 557 |
| NCT01780987Venous Thrombosis · Japan | 3 | Completed | Pfizer | Sep 2014 | 80 |
| NCT01707394Thromboembolism · United States, Australia, Canada and more | 1 | Completed | Bristol-Myers Squibb | Jun 30, 2020 | 49 |
| NCT01437839Healthy · Singapore | 1 | Completed | Pfizer | Oct 2011 | 22 |
| NCT01340586Kidney Failure, Chronic · United States | 1 | Completed | Bristol-Myers Squibb | Sep 2011 | 18 |
| NCT01195727Venous Thromboembolism · United States, Belgium, Canada and more | 1 | Terminated | Bristol-Myers Squibb | Jun 14, 2012 | 13 |
| NCT00914641Thrombosis · United States | 1 | Completed | Pfizer | Aug 2009 | 16 |
| NCT00852397Acute Coronary Syndrome · Japan | 2 | Terminated | Pfizer | Dec 2010 | 151 |
| NCT00831441Acute Coronary Syndrome · United States, Argentina, Australia and more | 3 | Terminated | Bristol-Myers Squibb | Mar 2011 | 7,484 |
| NCT00787150Atrial Fibrillation · Japan | 2 | Completed | Pfizer | Sep 2009 | 222 |
| NCT00643201Venous Thrombosis · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Mar 2013 | 5,614 |
| NCT00633893Venous Thrombosis · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Aug 2012 | 2,711 |
| NCT00496769Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Nov 30, 2010 | 6,421 |
| NCT00457002Venous Thrombosis · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | May 2011 | 6,758 |
| NCT00452530Venous Thrombosis · Austria, Belgium, Brazil and more | 3 | Completed | Bristol-Myers Squibb | Jan 2009 | 3,221 |
| NCT00412984Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | May 25, 2011 | 20,976 |
| NCT00313300Acute Coronary Syndrome · United States, Austria, Belgium and more | 2 | Completed | Bristol-Myers Squibb | May 2008 | 1,741 |
| NCT00252005Venous Thrombosis · United States, Australia, Austria and more | 2 | Completed | Bristol-Myers Squibb | Feb 2007 | 520 |
| NCT00097357Venous Thrombosis · United States, Argentina, Australia and more | 3 | Completed | Bristol-Myers Squibb | Dec 2005 | 1,238 |
How it is read
Names in the registry
- “Apixaban”, 38 entries
- “Apixaban 5 MG”, 2 entries
- “apixaban”, 2 entries
- “Apixaban 5 mg Oral Tablet”, 1 entry
- “Apixaban 5MG”, 1 entry
Conditions, from the studies’ own filings
- Venous Thrombosis, 7 studies
- Atrial Fibrillation, 6 studies
- Thrombosis, 4 studies
- Acute Coronary Syndrome, 4 studies
- Venous Thromboembolism, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.